Zymeworks

ZYME

Market cap $1.21B

Overview Fund Activity

15.93 USD

+0.19

1.21%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

15.93

0.00

0%

1 day

1.21%

5 days

5.15%

1 month

10.93%

3 months

25.93%

6 months

26.63%

Year to date

7.78%

1 year

27.34%

5 years

-61.12%

10 years

22.54%

About: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Employees: 273

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

376% more call options, than puts

Call options by funds: $4.2M | Put options by funds: $883K

13% more capital invested

Capital invested by funds: $839M [Q1] → $949M (+$111M) [Q2]

13% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 55

7.52% more ownership

Funds ownership: 101.16% [Q1] → 108.69% (+7.52%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]

3% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 30

2% less funds holding

Funds holding: 183 [Q1] → 180 (-3) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$13

18% downside

Avg. target

$17.5

10% upside

High target

$22

38% upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Citigroup Yigal Nochomovitz	$22	Buy Maintained	11 Aug 2025
HC Wainwright & Co. Robert Burns	$13	Neutral Reiterated	3 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ZYME published over the past 30 days

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

I maintain my Strong Buy rating on Zymeworks Inc., driven by its robust ADC pipeline and upcoming pivotal zanidatamab data in late 2025. ZW171 was discontinued due to on-target off-tumor toxicity, but ZYME is pivoting to a trispecific T-cell engager, ZW209, for improved safety and efficacy. ZW191 and ZW251 ADCs leverage proprietary TOPO1i payloads, targeting large, high-need markets in ovarian and liver cancer with strong scientific rationale.

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks Inc. ZYME on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks halts development of cancer drug after trial setback

Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company's goals as a standalone therapy.

Zymeworks halts development of cancer drug after trial setback

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced its decision to voluntarily discontinue clinical development of ZW171, a T cell engager designed to target gynecological, thoracic, and digestive system cancers.

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:

Zymeworks Announces Participation in Upcoming Investor Conferences

Zacks Investment Research

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company's Board of Directors, effective August 10, 2025. Mr. Ciongoli and Mr. Landry were also appointed as members of the audit committee of the Board of Directors.

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kenneth H. Galbraith - Chairman of the Board, CEO & President Leone D.

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks Inc. (ZYME) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.52 per share. This compares to a loss of $0.26 per share a year ago.

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the three and six months ended June 30, 2025 and provided a summary of recent business highlights.

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™